Addex Therapeutics Ltd
ADXN
$5.89
-$0.01-0.17%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -80.41% | -91.82% | -93.83% | -93.19% | -87.35% |
| Total Other Revenue | 16.39% | 2,361.76% | 1,898.65% | 3,189.74% | 1,550.98% |
| Total Revenue | -50.85% | -55.97% | -70.70% | -79.60% | -81.84% |
| Cost of Revenue | -20.79% | -16.26% | -22.89% | -44.28% | -35.31% |
| Gross Profit | 6.63% | -20.59% | -49.13% | -31.96% | -407.91% |
| SG&A Expenses | 20.66% | 6.96% | -23.44% | -29.33% | -27.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.42% | 0.71% | -23.29% | -33.90% | -30.04% |
| Operating Income | -15.16% | -9.16% | 14.51% | 21.82% | 3.95% |
| Income Before Tax | -37.88% | -48.58% | -40.28% | -67.05% | -96.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.88% | -48.58% | -40.28% | -67.05% | -96.64% |
| Earnings from Discontinued Operations | -99.13% | -98.95% | -98.86% | -98.61% | 267.42% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -191.37% | -207.56% | -226.24% | -255.09% | 174.52% |
| EBIT | -15.16% | -9.16% | 14.51% | 21.82% | 3.95% |
| EBITDA | -24.32% | -17.12% | 10.42% | 21.51% | 10.71% |
| EPS Basic | -180.35% | -198.96% | -232.08% | -314.85% | 162.83% |
| Normalized Basic EPS | -21.78% | -36.44% | -31.09% | -53.06% | -66.94% |
| EPS Diluted | -180.35% | -198.96% | -232.08% | -321.56% | 161.20% |
| Normalized Diluted EPS | -21.78% | -36.44% | -31.09% | -53.06% | -66.94% |
| Average Basic Shares Outstanding | 14.32% | 9.41% | 7.73% | 10.03% | 17.99% |
| Average Diluted Shares Outstanding | 14.32% | 9.41% | 7.73% | 10.03% | 17.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |